Jeff Johnson
Stock Analyst at Baird
(4.66)
# 187
Out of 4,980 analysts
147
Total ratings
59%
Success rate
29.47%
Average return
Main Sectors:
Stocks Rated by Jeff Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COO The Cooper Companies | Maintains: Outperform | $97 → $85 | $68.46 | +24.16% | 18 | Aug 28, 2025 | |
| ALC Alcon | Maintains: Outperform | $108 → $95 | $79.68 | +19.23% | 10 | Aug 21, 2025 | |
| BBNX Beta Bionics | Maintains: Neutral | $15 → $17 | $25.34 | -32.91% | 2 | Jul 30, 2025 | |
| HSIC Henry Schein | Downgrades: Neutral | $82 → $72 | $69.52 | +3.57% | 10 | Jul 14, 2025 | |
| NVST Envista Holdings | Upgrades: Outperform | $21 → $23 | $21.61 | +6.43% | 10 | May 27, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $130 → $115 | $104.26 | +10.30% | 14 | May 6, 2025 | |
| DXCM DexCom | Maintains: Outperform | $115 → $105 | $76.00 | +38.16% | 14 | May 2, 2025 | |
| TNDM Tandem Diabetes Care | Maintains: Neutral | $33 → $24 | $12.79 | +87.65% | 16 | May 1, 2025 | |
| SYK Stryker | Maintains: Outperform | $378 → $405 | $388.79 | +4.17% | 11 | Oct 30, 2024 | |
| ALGN Align Technology | Maintains: Outperform | $325 → $276 | $135.91 | +103.08% | 18 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $180 → $238 | $337.94 | -29.57% | 12 | Dec 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $70 | $31.58 | +121.66% | 2 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $61 | $15.34 | +297.65% | 4 | Jul 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $67 | $13.93 | +380.98% | 6 | Feb 18, 2022 |
The Cooper Companies
Aug 28, 2025
Maintains: Outperform
Price Target: $97 → $85
Current: $68.46
Upside: +24.16%
Alcon
Aug 21, 2025
Maintains: Outperform
Price Target: $108 → $95
Current: $79.68
Upside: +19.23%
Beta Bionics
Jul 30, 2025
Maintains: Neutral
Price Target: $15 → $17
Current: $25.34
Upside: -32.91%
Henry Schein
Jul 14, 2025
Downgrades: Neutral
Price Target: $82 → $72
Current: $69.52
Upside: +3.57%
Envista Holdings
May 27, 2025
Upgrades: Outperform
Price Target: $21 → $23
Current: $21.61
Upside: +6.43%
Zimmer Biomet Holdings
May 6, 2025
Maintains: Outperform
Price Target: $130 → $115
Current: $104.26
Upside: +10.30%
DexCom
May 2, 2025
Maintains: Outperform
Price Target: $115 → $105
Current: $76.00
Upside: +38.16%
Tandem Diabetes Care
May 1, 2025
Maintains: Neutral
Price Target: $33 → $24
Current: $12.79
Upside: +87.65%
Stryker
Oct 30, 2024
Maintains: Outperform
Price Target: $378 → $405
Current: $388.79
Upside: +4.17%
Align Technology
Oct 24, 2024
Maintains: Outperform
Price Target: $325 → $276
Current: $135.91
Upside: +103.08%
Dec 21, 2023
Upgrades: Outperform
Price Target: $180 → $238
Current: $337.94
Upside: -29.57%
Aug 4, 2023
Maintains: Outperform
Price Target: $67 → $70
Current: $31.58
Upside: +121.66%
Jul 28, 2023
Maintains: Outperform
Price Target: $53 → $61
Current: $15.34
Upside: +297.65%
Feb 18, 2022
Maintains: Outperform
Price Target: $78 → $67
Current: $13.93
Upside: +380.98%